Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 109 clinical trials
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

patients with multiple myeloma who have achieved at least partial response (PR) or better after receiving a bortezomib- and lenalidomide-containing combination front-line therapy.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma

achieved after first-line therapy. Currently, daratumumab (Dara) is approved by the american FDA and EMA in combination with lenalidomide (Len) and dexamethasone (Dex) or bortezomib and Dex for the

azoospermia
daratumumab
estrogen
dexamethasone
proteasome inhibitor
  • 0 views
  • 23 Jan, 2021
  • 1 location
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

The purpose of this study is to determine determine the maximum tolerated dose (MTD) and safety of the combination of Chidamide combined with CHOEP(cyclophosphamide epirubicin,vindesine, etoposide and prednisone) regimen as first line treatment in newly-diagnosed T-NHL.

peripheral t-cell lymphoma
cyclophosphamide
measurable disease
etoposide
ct scan
  • 3 views
  • 21 Jan, 2021
  • 1 location
Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

The study is designed as a randomized, controlled, open-label, assessor blind, multicenter superiority trial with three parallel groups, and primary endpoint of immunophenotypic complete responses at 18 months after randomization. Block randomization will be performed with a 1:1:1 allocation ratio. Patients will be randomized up front to 3 arms. Patients …

  • 13 views
  • 24 Mar, 2021
  • 89 locations
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd) Then Maintenance With Ixazomib (IXA) or IXA-Dara

This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara

bone marrow procedure
ejection fraction
anemia
velcade
calcium
  • 60 views
  • 27 Aug, 2021
  • 5 locations
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib

refractory multiple myeloma
bortezomib
measurable disease
cancer
pomalidomide
  • 2 views
  • 26 Jul, 2021
  • 74 locations
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

This is a study of venetoclax, daratumumab, and dexamethasone with and without bortezomib combination therapy to evaluate safety, tolerability, and efficacy of these combinations in participants

bone marrow procedure
electrophoresis
daratumumab
refractory multiple myeloma
bortezomib
  • 97 views
  • 23 Dec, 2021
  • 67 locations
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma the EQUATE Trial

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and

bone marrow procedure
measurable disease
prednisone
revlimid
chemotherapy regimen
  • 0 views
  • 09 Dec, 2021
  • 379 locations
  • 0 views
  • 09 Jan, 2022
  • 1 location
Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

treatment and remission gets shorter after each line of treatment. This is a study to determine recommended Phase 2 dose and change in disease symptoms of eftozanermin alfa in combination with bortezomib

refractory multiple myeloma
bortezomib
measurable disease
cancer
dexamethasone
  • 0 views
  • 10 Oct, 2021
  • 34 locations